Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2B known ✓ | P18089 | 1/20 | 0.95 |
| ▸ | PTGS1 known ✓ | P23219 | 1/20 | 0.95 |
| ▸ | CA2 known ✓ | P00918 | 3/20 | 0.60 |
| ▸ | GAA known ✓ | P10253 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.95 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.95 |
| ▸ | CA1 | P00915 | 3/20 | 0.60 |
| ▸ | CA7 | P43166 | 2/20 | 0.60 |
| ▸ | CA9 | Q16790 | 2/20 | 0.60 |
| ▸ | CA12 | O43570 | 1/20 | 0.60 |
| ▸ | CA4 | P22748 | 1/20 | 0.60 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.60 |
| ▸ | EP300 | Q09472 | 1/20 | 0.56 |
| ▸ | KAT8 | Q9H7Z6 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.52 |
| ▸ | MAPT | P10636 | 3/20 | 0.52 |
| ▸ | IDO1 | P14902 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | THRB | P10828 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4374714 | 1.00 | ALDH1A1 (0.95) | ALDH1A1TDP1ADRA2BPTGS1CA1 | |
| Hydrochloric Acid SCHEMBL27958987 | 1.00 | ALDH1A1 (0.95) | ALDH1A1TDP1ADRA2BPTGS1CA1 | |
| Hydrochloric Acid SCHEMBL30727463 | 1.00 | ALDH1A1 (0.95) | ALDH1A1TDP1ADRA2BPTGS1CA1 | |
| Hydrochloric Acid SCHEMBL28179944 | 0.97 | ALDH1A1 (0.90) | ALDH1A1TDP1ADRA2BPTGS1CA1 | |
| SCHEMBL14598 | 0.97 | — | — | |
| SCHEMBL29390378 | 0.97 | — | — | |
| SCHEMBL6469327 | 0.95 | ALDH1A1 (0.95) | ALDH1A1TDP1ADRA2BPTGS1CA1 | |
| SCHEMBL7772203 | 0.95 | ALDH1A1 (0.95) | ALDH1A1TDP1ADRA2BPTGS1CA1 | |
| SCHEMBL21840888 | 0.95 | ALDH1A1 (0.95) | ALDH1A1TDP1ADRA2BPTGS1CA1 | |
| SCHEMBL30366767 | 0.95 | ALDH1A1 (0.95) | ALDH1A1TDP1ADRA2BPTGS1CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 87 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2906535-B1 | INDOLINES | HOFFMANN LA ROCHE (CH) | 2018-08-08 | — | — | EP | claimed |
| EP-2367822-B1 | TRICYCLIC AZAINDOLES | MERCK PATENT GMBH (DE) | 2016-10-05 | — | — | EP | claimed |
| US-9403768-B2 | Indolines | HOFFMANN-LA ROCHE INC. (US) | 2016-08-02 | — | — | US | claimed |
| US-20150246882-A1 | INDOLINES | HOFFMANN-LA ROCHE INC. | 2015-09-03 | — | — | US | claimed |
| EP-2906535-A1 | INDOLINES | F. Hoffmann-La Roche AG (CH) | 2015-08-19 | — | — | EP | claimed |
| WO-2014056755-A1 | INDOLINES | F. HOFFMANN-LA ROCHE AG (CH) | 2014-04-17 | — | — | WO | claimed |
| EP-2367822-A1 | TRICYCLIC AZAINDOLES | Merck Patent GmbH (DE) | 2011-09-28 | — | — | EP | claimed |
| WO-2010080253-A1 | TRICYCLIC AZAINDOLES | MERCK PATENT GMBH (DE) | 2010-07-15 | — | — | WO | claimed |
| EP-1330448-A2 | 1,3-BIS-(SUBSTITUTED-PHENYL)-2-PROPEN-1-ONES AND THEIR USE TO TREAT VCAM-1 MEDIATED DISORDERS | Atherogenics, Inc. (US) | 2003-07-30 | — | — | EP | claimed |
| WO-2001098291-A2 | 1,3-BIS-(SUBSTITUTED-PHENYL)-2-PROPEN-1-ONES AND THEIR USE TO TREAT VCAM-1 MEDIATED DISORDERS | ATHEROGENICS, INC. (US) | 2001-12-27 | — | — | WO | claimed |
| JP-2304072-A | — | — | None | — | — | JP | disclosed |
| CN-118125995-A | Synthesis method of 1- (2-methoxyphenyl) piperazine hydrochloride | 南昌大学抚州医学院 | 2024-06-04 | — | — | CN | disclosed |
| CN-111375928-A | Flux for jet welding and welding method | 荒川化学工业株式会社 | 2020-07-07 | — | — | CN | disclosed |
| CN-110396049-A | The method for being used to prepare -1,4- phenylenediamine and its salt of 2- substitution | NOXELL CORP | 2019-11-01 | — | — | CN | disclosed |
| EP-2906535-B1 | INDOLINES | HOFFMANN LA ROCHE (CH) | 2018-08-08 | — | — | EP | disclosed |
| JP-H02304072-A | PRODUCTION OF ALPHA,BETA-EPOXYAMIDE | SANKYO CO LTD | 1990-12-17 | — | — | JP | disclosed |
| EP-0307078-A1 | Quinoline derivatives, process for their preparation and pharmaceutical compositions containing them | SMITHKLINE BEECHAM INTERCREDIT B.V. (NL) | 1989-03-15 | — | — | EP | disclosed |
| US-4224025-A | Process for the dyeing and printing of paper materials in different hues using a single coupling component | CIBA-GEIGY CORPORATION (US) | 1980-09-23 | — | — | US | disclosed |
| US-4165967-A | HYDROXY-PYRIDINE OR PYRIDONE COUPLERS | HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) | 1979-08-28 | — | — | US | disclosed |
| US-4065254-A | DIAZO DYES, LEATHER, COTTON, WOOL | CIBA-GEIGY CORPORATION (US) | 1977-12-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150246882-A1 | INDOLINES | IDO1, INMT, CCNY | ADRA2B 178/4885PTGS1 3053/4885CA2 1802/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.